Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

The Value of Phenotypes in Knee Osteoarthritis Research.

Nelson FRT.

Open Orthop J. 2018 Mar 16;12:105-114. doi: 10.2174/1874325001812010105. eCollection 2018. Review.

2.

A background for the management of osteoarthritic knee pain.

Nelson FR.

Pain Manag. 2014;4(6):427-36. doi: 10.2217/pmt.14.40. Review.

PMID:
25494694
3.

Subchondral insufficiency fractures and spontaneous osteonecrosis of the knee may not be related to osteoporosis.

Nelson FR, Craig J, Francois H, Azuh O, Oyetakin-White P, King B.

Arch Osteoporos. 2014;9:194. doi: 10.1007/s11657-014-0194-z. Epub 2014 Sep 19.

PMID:
25234658
4.

Erratum to: The effects of an oral preparation containing hyaluronic acid (Oralvisc(®)) on obese knee osteoarthritis patients determined by pain, function, bradykinin, leptin, inflammatory cytokines, and heavy water analyses.

Nelson FR, Zvirbulis RA, Zonca B, Li KW, Turner SM, Pasierb M, Wilton P, Martinez-Puig D, Wu W.

Rheumatol Int. 2015 Jan;35(1):53. doi: 10.1007/s00296-014-3078-z. No abstract available.

PMID:
24985363
5.

The effects of an oral preparation containing hyaluronic acid (Oralvisc®) on obese knee osteoarthritis patients determined by pain, function, bradykinin, leptin, inflammatory cytokines, and heavy water analyses.

Nelson FR, Zvirbulis RA, Zonca B, Li KW, Turner SM, Pasierb M, Wilton P, Martinez-Puig D, Wu W.

Rheumatol Int. 2015 Jan;35(1):43-52. doi: 10.1007/s00296-014-3047-6. Epub 2014 Jun 5. Erratum in: Rheumatol Int. 2015 Jan;35(1):53.

PMID:
24899570
7.

Using hip measures to avoid misdiagnosing early rapid onset osteoarthritis for osteonecrosis.

Nelson FR, Bhandarkar VS, Woods TA.

J Arthroplasty. 2014 Jun;29(6):1243-7. doi: 10.1016/j.arth.2013.11.010. Epub 2013 Nov 22.

PMID:
24360489
9.

Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors.

Claffey MM, Helal CJ, Verhoest PR, Kang Z, Fors KS, Jung S, Zhong J, Bundesmann MW, Hou X, Lui S, Kleiman RJ, Vanase-Frawley M, Schmidt AW, Menniti F, Schmidt CJ, Hoffman WE, Hajos M, McDowell L, O'Connor RE, Macdougall-Murphy M, Fonseca KR, Becker SL, Nelson FR, Liras S.

J Med Chem. 2012 Nov 8;55(21):9055-68. doi: 10.1021/jm3009635. Epub 2012 Oct 12.

PMID:
23025719
10.

A non-brain penetrant PDE5A inhibitor improves functional recovery after stroke in rats.

Menniti FS, Ren J, Sietsma DK, Som A, Nelson FR, Stephenson DT, Tate BA, Finklestein SP.

Restor Neurol Neurosci. 2012;30(4):283-9. doi: 10.3233/RNN-2012-110187.

PMID:
22596355
11.

Osteoarthritis and metabolic syndrome.

Nelson FR.

J Am Acad Orthop Surg. 2012 Apr;20(4):259-60. doi: 10.5435/JAAOS-20-04-259. No abstract available.

PMID:
22474096
12.

Non-invasive electromagnetic field therapy produces rapid and substantial pain reduction in early knee osteoarthritis: a randomized double-blind pilot study.

Nelson FR, Zvirbulis R, Pilla AA.

Rheumatol Int. 2013 Aug;33(8):2169-73. doi: 10.1007/s00296-012-2366-8. Epub 2012 Mar 27.

PMID:
22451021
13.

Preface: long-term effects of musculoskeletal tissue scaffolds.

Nelson FR.

J Long Term Eff Med Implants. 2012;22(3):x-xi. No abstract available.

PMID:
23582119
14.

Age and BMI variations in bone, muscle, and fat on AP mid-thigh radiographs.

Wildt D, Nelson FR.

J Long Term Eff Med Implants. 2012;22(3):245-51.

PMID:
23582117
15.

The paths of musculoskeletal scaffold research leading to long-term effects.

Nelson FR.

J Long Term Eff Med Implants. 2012;22(3):237-342. Review.

PMID:
23582115
16.

Discovery of two clinical histamine H(3) receptor antagonists: trans-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and trans-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]-N-(2-methylpropyl)cyclobutanecarboxamide (PF-03654764).

Wager TT, Pettersen BA, Schmidt AW, Spracklin DK, Mente S, Butler TW, Howard H, Lettiere DJ, Rubitski DM, Wong DF, Nedza FM, Nelson FR, Rollema H, Raggon JW, Aubrecht J, Freeman JK, Marcek JM, Cianfrogna J, Cook KW, James LC, Chatman LA, Iredale PA, Banker MJ, Homiski ML, Munzner JB, Chandrasekaran RY.

J Med Chem. 2011 Nov 10;54(21):7602-20. doi: 10.1021/jm200939b. Epub 2011 Oct 7.

PMID:
21928839
17.

Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia.

Helal CJ, Kang Z, Hou X, Pandit J, Chappie TA, Humphrey JM, Marr ES, Fennell KF, Chenard LK, Fox C, Schmidt CJ, Williams RD, Chapin DS, Siuciak J, Lebel L, Menniti F, Cianfrogna J, Fonseca KR, Nelson FR, O'Connor R, MacDougall M, McDowell L, Liras S.

J Med Chem. 2011 Jul 14;54(13):4536-47. doi: 10.1021/jm2001508. Epub 2011 Jun 8.

PMID:
21650160
18.

On the Horizon From the ORS.

Grande DA, Shah NV, Catanzano A, Nelson FRT, Hoey D, Jacobs C.

J Am Acad Orthop Surg. 2011 Jan;19(1):59-62. No abstract available.

PMID:
29329125
19.

Oral bioavailability of P-glycoprotein substrate drugs do not differ between ABCB1-1Δ and ABCB1 wild type dogs.

Mealey KL, Waiting D, Raunig DL, Schmidt KR, Nelson FR.

J Vet Pharmacol Ther. 2010 Oct;33(5):453-60. doi: 10.1111/j.1365-2885.2010.01170.x.

PMID:
20840389
20.

Understanding the clinical pharmacokinetics of a GABAA partial agonist by application of in vitro tools.

Sawant AD, Miller EL, Duignan DB, Brodfuehrer J, Winter SM, Nelson FR, Kamel A, Obach RS, Vaz AD.

Xenobiotica. 2010 Jul;40(7):476-84. doi: 10.3109/00498254.2010.481057.

PMID:
20429841
21.

Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy.

Verhoest PR, Proulx-Lafrance C, Corman M, Chenard L, Helal CJ, Hou X, Kleiman R, Liu S, Marr E, Menniti FS, Schmidt CJ, Vanase-Frawley M, Schmidt AW, Williams RD, Nelson FR, Fonseca KR, Liras S.

J Med Chem. 2009 Dec 24;52(24):7946-9. doi: 10.1021/jm9015334.

PMID:
19919087
22.
23.

Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.

Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, Hoffman WE, Lebel LA, McCarthy SA, Nelson FR, Proulx-LaFrance C, Majchrzak MJ, Ramirez AD, Schmidt K, Seymour PA, Siuciak JA, Tingley FD 3rd, Williams RD, Verhoest PR, Menniti FS.

J Pharmacol Exp Ther. 2008 May;325(2):681-90. doi: 10.1124/jpet.107.132910. Epub 2008 Feb 20.

PMID:
18287214
24.

Ethical safeguards for industry-funded research in an academic setting.

Nelson FR, Hay N.

J Long Term Eff Med Implants. 2008;18(2):175-9.

PMID:
19968626
25.

Peripheral elevation of IGF-1 fails to alter Abeta clearance in multiple in vivo models.

Lanz TA, Salatto CT, Semproni AR, Marconi M, Brown TM, Richter KE, Schmidt K, Nelson FR, Schachter JB.

Biochem Pharmacol. 2008 Mar 1;75(5):1093-103. Epub 2007 Nov 12.

PMID:
18076866
26.

Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures.

Venkatakrishnan K, Tseng E, Nelson FR, Rollema H, French JL, Kaplan IV, Horner WE, Gibbs MA.

Drug Metab Dispos. 2007 Aug;35(8):1341-9. Epub 2007 Apr 30.

PMID:
17470526
27.

On the horizon from the ORS.

Gibson G, Nelson FR, Fyhrie D.

J Am Acad Orthop Surg. 2006 Jul;14(7):445-6. No abstract available.

PMID:
16822892
28.

Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration.

Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, Hosea N, Liu J, Nelson FR, Szewc MA, Van Deusen J.

Drug Metab Dispos. 2006 Sep;34(9):1443-7. Epub 2006 Jun 7.

PMID:
16760229
29.

On the horizon from the ORS.

Fyhrie D, Nelson FR, Gibson G.

J Am Acad Orthop Surg. 2006 Apr;14(4):256-8. No abstract available.

PMID:
16585367
30.

Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding.

Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, Hosea N, Liu J, Nelson FR, Szewc MA, Van Deusen J.

J Pharmacol Exp Ther. 2005 Jun;313(3):1254-62. Epub 2005 Mar 2.

PMID:
15743928
31.

The orthopaedic surgeon's standard of living versus quality of life.

Nelson FR.

J Bone Joint Surg Am. 2004 Jan;86(1):182-3. No abstract available.

PMID:
14711964
32.

Use of physical forces in bone healing.

Nelson FR, Brighton CT, Ryaby J, Simon BJ, Nielson JH, Lorich DG, Bolander M, Seelig J.

J Am Acad Orthop Surg. 2003 Sep-Oct;11(5):344-54. Review.

PMID:
14565756
33.

Bilateral subchondral cysts without arthroscopic evidence of articular cartilage degradation.

Bradley MP, Provencher MT, Nelson FR.

Arthroscopy. 2002 Oct;18(8):E41.

PMID:
12368801
35.

Iliac crest bone-muscle transfer in periacetabular osteotomy.

Santore R, Nelson FR, Muldoon M.

Orthopedics. 2000 Mar;23(3):207-9.

PMID:
10741364
37.
38.
39.

Disposition of acrivastine in the male beagle dog.

McNulty MJ, Deal DL, Nelson FR, Weller S, Chandrasurin P, Shockcor J, Findlay JW.

Drug Metab Dispos. 1992 Sep-Oct;20(5):679-87.

PMID:
1358572
40.

Quantitative gas chromatographic-mass spectrometric analysis of acrivastine and a metabolite in human plasma.

Chang SY, Nelson FR, Findlay JW, Taylor LC.

J Chromatogr. 1989 Dec 29;497:288-95. No abstract available.

PMID:
2576270
41.

Orthopedic history and examination in the etiology of overuse injuries.

Montgomery LC, Nelson FR, Norton JP, Deuster PA.

Med Sci Sports Exerc. 1989 Jun;21(3):237-43.

PMID:
2733571
42.

Effects of selected insect growth regulators and pesticides on Dugesia dorotocephala and Dugesia tigrina (Tricladida: Turbellaria).

Nelson FR, Edmond M, Mohamed AK.

J Am Mosq Control Assoc. 1988 Jun;4(2):184-6. No abstract available.

PMID:
3193116
43.

Compatibility of Metarhizium anisopliae var. anisopliae with chemical pesticides.

Mohamed AK, Pratt JP, Nelson FR.

Mycopathologia. 1987 Aug;99(2):99-105.

PMID:
3657906
44.
45.

Anti-estrogenic action of chlordecone in rat pituitary gonadotrophs in vitro.

Huang ES, Nelson FR.

Toxicol Appl Pharmacol. 1986 Jan;82(1):62-9.

PMID:
2418533
46.

Efficacy of three insect growth regulators on the development of Aedes aegypti.

Nelson FR, Mohamed AK, Vattikutti P.

J Am Mosq Control Assoc. 1985 Jun;1(2):240-2. No abstract available.

PMID:
3880238
47.

Effects of benzylphenol and benzyl-1,3-benzodioxole derivatives on fertility and longevity of the yellow fever mosquito (Diptera:Culicidae).

Nelson FR, Hoosseintehrani B.

J Econ Entomol. 1982 Oct;75(5):877-8. No abstract available.

PMID:
7175006
49.

Skilled orders get skilled care.

Nelson FR, Britton LE.

Md State Med J. 1979 Feb;28(2):75-7. No abstract available.

PMID:
423623
50.

Pathologic changes induced in respiratory tract mucosa by polycyclic hydrocarbons of differing carcinogenic activity.

Topping DC, Pal BC, Martin DH, Nelson FR, Nettesheim P.

Am J Pathol. 1978 Nov;93(2):311-24.

Supplemental Content

Loading ...
Support Center